Bionic instant microneedle patch as well as preparation method and application thereof

Through the use of bionic instant microneedle patches, the problem of incomplete cure and excessive autoimmune response in vitiligo treatment has been solved, and rapid recoloration and immune regulation have been achieved. CD8+ is inhibited through the binding of immunosuppressants and bionic nanomelanocytes. T cell activation improves vitiligo's efficacy and shows potential applications in other autoimmune diseases.

CN118948733AActive Publication Date: 2024-11-15OCEAN UNIV OF CHINA

Patent Information

Application Number
CN202411038929.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-31
Publication Date
2024-11-15
Estimated Expiration
2044-07-31

AI Technical Summary

Technical Problem

The existing treatment methods for vitiligo cannot be completely cured, and excessive autoimmune responses lead to multiple complications and psychological effects, and the lack of melanocytes causes keratinocytes to be susceptible to oxidative damage and intensify inflammation.

Method used

Provide a bionic instant microneedle patch containing immunosuppressants, bionic nanomelanocytes and needle polymers. It quickly dissolves and releases immunosuppressants and nanomelanin after being penetrated into the skin through microneedles, mimicking the light protection of natural melanocytes and Free radical scavenging function and inhibit CD8+ T cell activation by engineered cell membrane transfer.

Benefits of technology

It has achieved rapid recoloring and immune regulation of vitiligo, saved time to use drugs, effectively inhibited autoimmune killing, improved the efficacy of vitiligo, and had good clinical application prospects in other autoimmune diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948733A_ABST
    Figure CN118948733A_ABST
Patent Text Reader

Abstract

The invention relates to a bionic instant microneedle patch as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The bionic instant micro-needle patch comprises a micro-needle body and a backing, the microneedle body comprises an immunosuppressive agent, bionic nano melanocytes and a needle body polymer; the backing is prepared from a backing polymer solution. The instant microneedle patch has the functions of rapid color recovery, inflammation reduction and immune regulation, the needle tip is rapidly dissolved and releases an immunosuppressant, ROS removal components and nano melanin after the microneedle pierces the skin, rapid color recovery and immune regulation of the skin of the vitiligo part are achieved, the medication time is saved, and rapid color recovery of a decolored area is achieved; the instant microneedle patch disclosed by the invention realizes melanocyte escape autoimmune killing and vitiligo improvement curative effects by releasing an immunosuppressive agent and shaping an immunosuppressive microenvironment of a bionic tumor, and has a good clinical application transformation prospect in treatment of other autoimmune diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a bionic fast-dissolving microneedle patch and a preparation method and application thereof, belonging to the technical field of biomedicine. Background Art

[0002] Vitiligo is a common skin depigmentation disease that is closely related to the death of melanocytes mediated by the immune system, affecting approximately 0.1-2% of the global population. Autoimmune reactions caused by factors such as immune system disorders, genetic factors, or chemicals specifically attack melanocytes, causing their death and forming vitiligo. Although vitiligo is a chronic disease that is not life-threatening, overly strong autoimmune reactions often lead to multiple complications. In addition, exposed white patches can seriously affect the patient's mental state. At present, the clinical treatment of vitiligo mainly includes physical masking agents, immunosuppressants, hormones, transplantation, and phototherapy. However, these strategies are subject to the multiple pathogenesis of vitiligo and cannot be completely cured.

[0003] Reactive oxygen species (ROS) are an important factor inducing vitiligo, which can cause oxidative stress damage to melanocytes and inflammatory cascades. Under normal circumstances, melanin is produced by melanocytes and transported to surrounding keratinocytes, and plays a variety of biological functions including pigmentation, photoprotection, and ROS scavenging. However, the lack of melanin in the vitiligo area makes keratinocytes more susceptible to oxidative damage caused by various stimuli, exacerbating inflammation and immune responses.

[0004] Endogenous CD8+T cell targeted killing is the main cause of melanocyte death. Clinical statistics show that the risk of melanoma in patients with vitiligo is significantly lower than that of the general population, while the risk of vitiligo in patients with melanoma is more than 7 times higher than that of the normal population. Since melanoma cells share antigens with melanocytes (Me l an-A, gp100 and tyrosinase), 2-18% of melanoma patients develop vitiligo after immunotherapy, which verifies the good immune efficacy. The tumor microenvironment can inhibit the activity of T lymphocytes due to high levels of lactic acid, such as inhibiting CD8+T cell activation and reducing immune clearance ability, and enhancing regulatory T cell (Treg) activity to aggravate immunosuppression. In addition, the programmed death ligand 1 (PD-L1) molecule expressed on the surface of tumor cells binds to PD-1 on the surface of T lymphocytes, reducing the activity of T cells, inhibiting the proliferation of T cells, inducing T cell apoptosis and disintegration, and cancer cells obtain self-rescue, thereby achieving immune escape. Summary of the invention

[0005] The purpose of the present invention is to provide a bionic fast-dissolving microneedle patch and a preparation method and application thereof to solve the technical problems existing in the prior art as described above.

[0006] The technical solution provided by the present invention is as follows:

[0007] One of the purposes of the present invention is to provide a bionic fast-dissolving microneedle patch, comprising a microneedle body and a backing; the microneedle body comprises an immunosuppressant, bionic nano-melanocytes and a needle body polymer; the backing is prepared from a backing polymer solution.

[0008] On the basis of the above technical solution, the present invention can also be improved as follows:

[0009] Furthermore, the immunosuppressant is lactic acid, sucralose, itaconic acid, anti-IL-2 receptor monoclonal antibody, FTYZO, rapamycin, mycophenolate, tacrolimus or cyclosporine; the needle body polymer is composed of a supporting component and a disintegrant; the concentration of the bionic nano-melanocytes is 1 to 2000 μg / mL; and the mass fraction of the backing polymer solution is 3 to 60%.

[0010] Furthermore, the supporting component is cyclodextrin or maltodextrin; the disintegrant is starch, carboxymethyl cellulose, fucoidan, polyvinyl pyrrolidone, cellulose or sodium carboxymethyl starch; and the backing polymer is polyvinyl alcohol, chitosan, hyaluronic acid or sodium alginate.

[0011] Furthermore, the bionic nano-melanocytes are made of bionic melanin nanoparticles coated with engineered cell membranes.

[0012] Furthermore, the bionic melanin nanoparticles are polydopamine bionic melanin nanoparticles, polydopa bionic melanin nanoparticles or cuttlefish juice bionic melanin nanoparticles, and the engineered cell membrane is a melanoma cell B16F10 cell membrane, a melanocyte cell membrane or a regulatory T cell cell membrane.

[0013] Furthermore, the preparation method of the polydopa biomimetic melanin nanoparticles comprises the following steps: firstly, dissolving polydopa in deionized water to obtain a polydopa solution, and then placing the solution in a water bath to heat and stir for reaction to obtain polydopa biomimetic melanin nanoparticles.

[0014] Furthermore, the concentration of the polydopa solution is 0.1-10 mg / mL.

[0015] Furthermore, the temperature of the heating and stirring reaction is 60-100° C., and the reaction time is 4-48 hours.

[0016] Furthermore, the engineered cell membrane overexpresses PD-L1, CD3L1, FGF21, galectin-3, LSECtin, FGL1, galectin-8, galectin-9 or CTLA4.

[0017] Furthermore, the engineered cell membrane overexpressing PD-L1 is achieved by treating living cells with IFN-γ or Poly(I:C) or chemically modifying PD-L1 on the cell surface by EDC / NHS.

[0018] The second object of the present invention is to provide a method for preparing the bionic fast-dissolving microneedle patch as described above, comprising the following steps: adding immunosuppressants and bionic nano-melanocytes to a needle body polymer, mixing to obtain a premixed solution, injecting the solution into a microneedle mold, centrifuging to allow the premixed solution to fill the mold cavity, removing excess needle tip premixed solution and immediately evenly covering the needle tip with a backing polymer solution, then drying and demolding to obtain a bionic fast-dissolving microneedle patch.

[0019] Furthermore, the drying time is 6 to 36 hours, the temperature is 4 to 36° C., and the humidity is 5 to 60%.

[0020] The third object of the present invention is to provide an application of the bionic fast-dissolving microneedle patch as described above in the preparation of a microneedle patch for treating autoimmune diseases.

[0021] Furthermore, the autoimmune disease includes vitiligo.

[0022] Compared with the prior art, the technical solution provided by the present invention has the following beneficial effects:

[0023] (1) The bionic nano-melanocytes of the present invention can simulate natural melanocytes to provide melanin, play a role in light protection and free radical scavenging.

[0024] (2) The instant microneedle patch of the present invention has the functions of rapid re-pigmentation, reducing inflammation and immune regulation. The needle tip of the microneedle body is constructed by an open network structure. After the microneedle penetrates the skin, the needle tip dissolves rapidly, releasing immunosuppressants, ROS scavenging components and nano-melanin, thereby achieving rapid re-pigmentation and immune regulation of the skin in the vitiligo area, saving medication time and achieving rapid re-pigmentation of the depigmented area.

[0025] (3) The fast-dissolving microneedle patch of the present invention releases immunosuppressants and transfers engineered cell membranes that overexpress immune checkpoint inhibitors to damaged melanocytes, thereby shaping the immunosuppressive microenvironment of bionic tumors, effectively inhibiting the activation of specific CD8+T cells, allowing melanocytes to escape autoimmune killing, improving the efficacy of vitiligo, and having good prospects for clinical application transformation in the treatment of other autoimmune diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 Transmission electron microscope image of polydopa biomimetic melanin nanoparticles;

[0027] Figure 2 Transmission electron microscope image of biomimetic nanomelanocytes;

[0028] Figure 3 The particle size distribution of polydopa biomimetic melanin nanoparticles and biomimetic nanomelanocytes;

[0029] Figure 4 is the absorption spectrum of polydopa biomimetic melanin nanoparticles;

[0030] Figure 5 DPPH free radical scavenging for polydopa biomimetic melanin nanoparticles;

[0031] Figure 6 ABTS free radical scavenging for polydopa biomimetic melanin nanoparticles;

[0032] Figure 7 This is the fluorescence image after co-incubation of bionic nanomelanocytes and Hacat cells;

[0033] Figure 8 Transmission electron microscope image of bionic nanomelanocytes co-incubated with Hacat cells;

[0034] Fig. 9 Live / dead staining images of Hacat cells after treatment with different concentrations of biomimetic nanomelanin cells;

[0035] Fig.10 CCK-8 was used to detect the survival rate of Hacat cells;

[0036] Fig.11 Schematic diagram of the preparation of the fast-dissolving microneedle patch;

[0037] Fig.12 This is an optical image of the instant dissolving microneedle;

[0038] Fig.13 This is a scanning electron microscope image of the instant-dissolving microneedle;

[0039] Fig.14 This is a laser confocal 3D scanning image of the instant microneedle;

[0040] Fig.15 is the force-displacement curve of the instant microneedle;

[0041] Fig.16 This is a trypan blue staining image of mouse skin after application of the fast-dissolving microneedle patch;

[0042] Fig.17 Laser confocal scanning images of mouse skin at different depths after application of the fast-dissolving microneedle patch;

[0043] Fig.18 This is a microscopic observation image after the application of the quick-dissolving microneedle patch;

[0044] Fig.19 is the in vitro release curve of BNM and Lac in the fast-dissolving microneedles;

[0045] Fig. 20 Optical image of the skin after application of the fast-dissolving microneedle patch;

[0046] Fig.21 Continuous observation of the skin in the treated area of ​​the vitiligo mice;

[0047] Fig. 22 The melanin content in the skin of the treated area of ​​the vitiligo mice;

[0048] Fig.23 This is Masson-Fontana staining of the skin on the 7th day of treatment;

[0049] Fig.24 Masson-Fontana staining of the skin on day 21 of treatment. DETAILED DESCRIPTION

[0050] The principles and features of the present invention are described below in conjunction with examples. The examples are only used to explain the present invention and are not used to limit the scope of the present invention.

[0051] Example 1: Preparation and performance testing of polydopa biomimetic nano-melanocytes

[0052] 1. Preparation of polydopa biomimetic nano-melanocytes

[0053] 2 mg / mL L-DOPA was dissolved in deionized water and reacted at 80°C with stirring for 24 hours to prepare polydopa bionic melanin nanoparticles. B16F10 cells overexpressing PD-L1 were disrupted by repeated freeze-thaw method, and the cell membrane was obtained by differential centrifugation. The cell membrane and polydopa bionic melanin nanoparticles were co-extruded to prepare polydopa bionic nanomelanocytes.

[0054] 2. Morphological characterization of polydopa biomimetic nanomelanocytes

[0055] The above polydopa biomimetic nano-melanocytes were observed by transmission electron microscopy and the particle size distribution was analyzed by DLS particle size analyzer. Figure 1-3 shown.

[0056] like Figure 1 As shown, polydopa biomimetic melanin nanoparticles are spherical and uniform in size; Figure 2 As shown, the polydopa biomimetic nano-melanin cells present a double-layer structure, and the polydopa biomimetic melanin nanoparticles are wrapped by the cell membrane; Figure 3 As shown, the average particle size of polydopa biomimetic melanin nanoparticles is 102 nm, and the average particle size of polydopa biomimetic nanomelanin cells is slightly increased.

[0057] 3. Characterization of the properties of polydopa biomimetic melanin nanoparticles

[0058] The absorbance of the polydopa biomimetic melanin nanoparticles was measured by UV-visible spectrophotometry. At the same time, DPPH and ABTS were used to detect the free radical scavenging ability of the polydopa biomimetic melanin nanoparticles. Figure 4-6 shown.

[0059] like Figure 4 As shown, polydopa biomimetic melanin nanoparticles are similar to natural melanin and have the ability to absorb broad spectrum light; Figure 5 As shown in the figure, polydopa biomimetic melanin nanoparticles have the ability to scavenge DPPH free radicals, and the average scavenging rate of DPPH at 200 μg / mL is 82.41%; Figure 6 As shown, polydopa biomimetic melanin nanoparticles have the ability to scavenge ABTS free radicals, and the average scavenging rate of ABTS at 200 μg / mL is 92.61%.

[0060] In summary, the prepared polydopa biomimetic nanomelanocytes have uniform particle size and have broad-spectrum light absorption and free radical scavenging capabilities.

[0061] Example 2: Evaluation of the efficacy of polydopa biomimetic nano-melanocytes in transferring melanin to protect keratinocytes

[0062] 1. The ability of polydopa biomimetic nanomelanocytes to deliver melanin

[0063] The polydopa bionic nano-melanocytes prepared in Example 1 were co-incubated with human keratinocytes Hacat; the polydopa bionic nano-melanocytes were labeled with Di I, and after co-incubation with Hacat cells, fluorescence microscopy was used to image the cells, and transmission electron microscopy was used to observe the melanin in the cells. The experimental results are shown in FIG. Figure 7-8 shown.

[0064] like Figure 7 As shown, DAPI-labeled Hacat cells co-localize with Di I-labeled polyDOPA biomimetic nanomelanocytes, proving that Hacat cells interact with polyDOPA biomimetic nanomelanocytes; Figure 8 As shown, polydopa biomimetic melanin nanoparticles were observed in Hacat cells, proving that polydopa biomimetic nanomelanocytes can simulate natural melanocytes to transfer melanin into keratinocytes.

[0065] 2. Evaluation of the efficacy of polydopa biomimetic nano-melanocytes in protecting keratinocytes

[0066] H2O2 and UV-B were used to construct a Hacat cell oxidative stress or UV damage model. After co-incubation with different concentrations of polydopa biomimetic nano-melanocytes, calcein / PI was used to stain Hacat cells, and CCK-8 was used to detect Hacat cell survival rate. The experimental results are shown in Figure 2. Figure 9-10 shown.

[0067] like Fig. 9 As shown, with the increase of the concentration of polydopa biomimetic nanomelanin cells, the number of dead cells labeled with PI in Hacat cells after H2O2 and UV-B stimulation was significantly reduced, and the number of live cells increased; Fig.10 As shown, polydopa biomimetic nanomelanocytes significantly increased the survival rate of Hacat cells after H2O2 and UV-B stimulation.

[0068] In summary, polydopa bionic nano-melanocytes can simulate natural melanocytes to provide melanin to keratinocytes, thereby protecting Hacat cells from cell damage mediated by external stimuli through broad-spectrum light absorption and free radical scavenging capabilities. Therefore, polydopa bionic nano-melanocytes can replace melanocytes for the re-pigmentation of vitiligo areas.

[0069] Example 3: Preparation and performance testing of fast-dissolving microneedle patches

[0070] 1. Preparation of fast-dissolving microneedle patches

[0071] like Fig.11 As shown, 30wt% maltodextrin, 2wt% fucoidan, 500μg / mL polydopa nanomelanocytes prepared in Example 1 and 100mM lactic acid were mixed evenly, and the obtained premixed solution was added to a microneedle mold and centrifuged at 3500rpm for 2min to fill the needle cavity with the premixed solution; the excess premixed solution outside the needle cavity was removed, and then immediately covered with a layer of 20wt% PVA (polyvinyl alcohol) solution, 50% humidity, dried at room temperature for 24h, and separated from the mold to obtain a fast-dissolving microneedle patch.

[0072] 2. Morphological characterization of the fast-dissolving microneedle patch

[0073] The above-mentioned fast-dissolving microneedle patch was observed by a camera or a scanning electron microscope. At the same time, the polydopa nanomelanocytes in the premixed solution were labeled with the lipophilic dye Di I, and the prepared fast-dissolving microneedle patch was observed by Z-axis scanning of a confocal laser microscope. The experimental results are shown in FIG. Figure 12-14 shown.

[0074] like Fig.12 As shown in the figure, the instant microneedle body has a distinct double-layer structure, the needle tip is black, the base is transparent, and the shape is uniform; Fig.13As shown in FIG, the instant microneedle body is pyramid-shaped, with a bottom side length of 300 μm and a height of 600 μm; Fig.14 As shown, DiI-labeled polydopa nano-melanocytes are concentrated in the tip of the fast-dissolving microneedle body.

[0075] 3. Skin piercing ability of instant microneedle body

[0076] The mechanical strength of the instant microneedle body was tested by a universal testing machine compression test. The instant microneedle patch was prepared into a 10*10 microneedle array and placed on a universal testing machine to test the pressure and displacement curve of the instant microneedle body after compression. The experimental results are shown in Fig.15 shown.

[0077] The skin piercing ability of the quick-dissolving microneedle body was studied using the back skin of C57BL / 6 mice. After the C57BL / 6 mice were anesthetized, the back hair was thoroughly cleaned with a depilatory cream, and the back skin was kept dry. The quick-dissolving microneedle body was inserted into the back skin of the mouse, and pressed with a force of about 15N for 1 minute. The undissolved backing was removed and stained with 0.2% trypan blue for 20 minutes and then observed. The experimental results are shown in the figure. Fig.16 shown.

[0078] The mouse skin was pierced with a quick-dissolving microneedle loaded with Di I-labeled polydopa nanomelanocytes, and the skin was observed by laser confocal 3D scanning. Fig.17 shown.

[0079] like Fig.15 As shown, a single microneedle tip can withstand a force of 0.6N; Fig.16 As shown in the figure, after the microneedles penetrated the skin, the tips of the microneedles were stained with trypan blue; Fig.17 As shown, the microneedles were able to penetrate the skin up to 490 μm.

[0080] 4. Dissolution and release performance of fast-dissolving microneedles

[0081] The fast-dissolving microneedles were placed in simulated body fluids, and the nano-melanocytes and lactic acid released from the solution were detected after different periods of time. Figure 18-19 shown.

[0082] Mouse skin after rapid microneedling. Fig. 20 shown.

[0083] like Fig.18 As shown in Figure 2, the microneedles dissolve rapidly within 1 minute after puncturing the skin; Fig.19 As shown, the nano-melanocytes and lactic acid loaded in the microneedles were rapidly released within 100 s in vitro; Fig. 20 As shown, nanomelanocytes released after microneedle dissolution were observed within the skin.

[0084] In summary, the fast-dissolving microneedles have sufficient mechanical strength to rapidly dissolve and release the nanomelanocytes and lactic acid loaded on the needle tip after puncturing the skin.

[0085] Example 4: Evaluation of the efficacy of the fast-dissolving microneedle patch in the treatment of vitiligo

[0086] In this example, C57BL / 6 mice were used. In the in vivo treatment experiment, a vitiligo mouse model was first constructed by applying 40% monobenzone cream for 60 consecutive days. The vitiligo mice with successful modeling were treated with tacrolimus cream, Lac / IMN, BNM / I MN and BNM+Lac / I MN, respectively, and compared with the untreated group. Normal mice were used as controls to observe the degree of color recoloration in the treated area. The melanin content of the skin was calculated by detecting the OD450 absorbance value of the supernatant after grinding. Masson-Fontana staining was performed on the mouse skin in the treated area. The experimental results are shown in Figure 2. Figure 21-24 shown.

[0087] like Fig.21 As shown in the figure, on the 7th day, only the skin of the treated area of ​​the BNM / I MN group and the BNM+Lac / I MN group was black. After 28 days of treatment, the hair grown in the untreated group lacked melanin, while the hair color of each treatment group improved to varying degrees. The hair color of the BNM+Lac / I MN group was closest to that of the control group, and was basically completely restored to color; Fig. 22 As shown, the melanin content in the BNM+Lac / I MN group was the highest, about 78% of that in the control group and higher than that in the tacrolimus group; Fig.23 As shown, on day 7, the hair follicles of all groups were in the resting phase, no growing hair follicles were observed, and exogenous melanin in the BNM was observed in the BNM / I MN and BNM+Lac / I MN groups; Fig.24 As shown, growing hair follicles were observed in all groups on day 21. Almost no melanin was observed in most of the hair follicles in the untreated group, a small amount of melanin was present in some of the hair follicles in the tacrolimus group, and in contrast, the melanin in the hair follicles of the BNM / I MN group and the BNM+Lac / I MN group was closer to that of the control group.

[0088] This shows that the fast-dissolving microneedle patch prepared by the present invention has a good effect in treating vitiligo and can be used to prepare vitiligo complex-colored microneedle patch.

[0089] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A bionic fast-dissolving microneedle patch, comprising a microneedle body and a backing, characterized in that: The microneedle body comprises an immunosuppressant, bionic nano-melanocytes and a needle body polymer; and the backing is prepared from a backing polymer solution.

2. A bionic fast-dissolving microneedle patch according to claim 1, characterized in that: The immunosuppressant is lactic acid, sucralose, itaconic acid, anti-IL-2 receptor monoclonal antibody, FTYZO, rapamycin, mycophenolate, tacrolimus or cyclosporine; the needle body polymer is composed of a supporting component and a disintegrant; the concentration of the bionic nano-melanocytes is 1 to 2000 μg / mL; and the mass fraction of the backing polymer solution is 3 to 60%.

3. A bionic fast-dissolving microneedle patch according to claim 2, characterized in that: The supporting component is cyclodextrin or maltodextrin; the disintegrant is starch, carboxymethyl cellulose, fucoidan, polyvinyl pyrrolidone, cellulose or sodium carboxymethyl starch; and the backing polymer is gelatin, polyvinyl alcohol, chitosan, hyaluronic acid or sodium alginate.

4. The bionic fast-dissolving microneedle patch according to claim 1, characterized in that: The bionic nano-melanocytes are made of bionic melanin nanoparticles coated with engineered cell membranes.

5. The bionic fast-dissolving microneedle patch according to claim 4, characterized in that: The bionic melanin nanoparticles are polydopamine bionic melanin nanoparticles, polydopa bionic melanin nanoparticles or cuttlefish juice bionic melanin nanoparticles, and the engineered cell membrane is a melanoma cell B16F10 cell membrane, a melanocyte cell membrane or a regulatory T cell cell membrane.

6. The bionic fast-dissolving microneedle patch according to claim 4, characterized in that: The engineered cell membrane overexpresses PD-L1, CD3L1, FGF21, galectin-3, LSECtin, FGL1, galectin-8, galectin-9 or CTLA4.

7. The bionic fast-dissolving microneedle patch according to claim 6, characterized in that: The engineered cell membrane overexpresses PD-L1 by treating living cells with IFN-γ or Poly(I:C) or chemically modifying PD-L1 on the cell surface by EDC / NHS.

8. A method for preparing a bionic fast-dissolving microneedle patch according to any one of claims 1 to 7, characterized in that: The following steps are involved: Immunosuppressants and bionic nanomelanocytes are added to the needle body polymer, mixed to obtain a premixed solution, injected into the microneedle mold, centrifuged to allow the premixed solution to fill the mold cavity, and immediately and evenly covered with the backing polymer solution after removing excess needle tip premixed solution, followed by drying and demolding to obtain a bionic instant microneedle patch.

9. The method for preparing a bionic fast-dissolving microneedle patch according to claim 8, characterized in that: The drying time is 6 to 36 hours, the temperature is 4 to 36° C., and the humidity is 5 to 60%.

10. Use of the bionic fast-dissolving microneedle patch according to any one of claims 1 to 7 in preparing a microneedle patch for treating autoimmune diseases.

Citation Information

Patent Citations

  • Eye implanted gel containing cyclosporin

    CN101085341A

  • Topical formulations based on ionic species for skin treatment

    CN109789216A

  • Transdermal drug delivery microneedle capable of effectively protecting drug activity

    CN114522136A

  • Double-layer drug-loaded microneedle for treating vitiligo as well as preparation method and application of double-layer drug-loaded microneedle

    CN118078762A

  • Lipid-biopolymer nanoparticles having antibody and autoantigen bound to surface thereof, and use thereof

    WO2022235125A1

Cited By

  • Temperature-sensitive hydrogel based on natural melanin and application thereof

    CN120022234A